Pacira BioSciences Management
Management criteria checks 1/4
Pacira BioSciences' CEO is Frank Lee, appointed in Jan 2024, has a tenure of 2.25 years. total yearly compensation is $15.94M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth $2.18M. The average tenure of the management team and the board of directors is 3 years and 2.5 years respectively.
Key information
Frank Lee
Chief executive officer
US$15.9m
Total compensation
| CEO salary percentage | 5.62% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
PCRX: Real World Hip Data And Activist Pressure Will Shape Outlook
Analysts have reduced their Pacira BioSciences price target by $2, citing updated real world data in hip arthroplasty and revisions to growth, margin, and future P/E assumptions. Analyst Commentary Bearish analysts are flagging that updated real world hip arthroplasty data has introduced more uncertainty into Pacira BioSciences' outlook, leading to more cautious assumptions around growth, margin profile, and future P/E levels.
PCRX: Higher 2026 Outlook And Activist Pressure Will Unlock Future Upside
Analysts have trimmed their Pacira BioSciences price target by $2, citing updated assumptions around faster revenue growth, a lower profit margin outlook, and a higher future P/E multiple. Analyst Commentary Despite the modest trim to the headline price target, bullish analysts see the updated assumptions as a way to reset expectations while keeping a constructive view on Pacira BioSciences.PCRX: Future Outlook Weighs Activist Board Push Against Asia Licensing Upside
Analysts have reaffirmed their $22.00 price target for Pacira BioSciences, noting small adjustments to revenue growth, profit margin assumptions, and a slightly lower future P/E multiple to reflect updated expectations for the company’s earnings profile. What's in the News DOMA Perpetual Capital Management nominated three director candidates for the 2026 annual meeting and called for the immediate replacement of CEO Frank Lee, the appointment of an interim CEO, and a formal sale process for the business (Investor activism, March 12, 2026).PCRX: Future Outlook Balances Asia Partnership Progress With Activist Pressure
Analysts have trimmed their price target on Pacira BioSciences from $24 to $22, reflecting updated assumptions that include a higher discount rate, more conservative revenue expectations, and lower projected profit margins, partly offset by a slightly higher future P/E multiple. What's in the News Issued full year 2026 earnings guidance, with total revenue expected in a range of $745 million to $770 million.PCRX: Asia Partnership Will Drive Future Upside Potential
Analysts have kept their $38.00 price target for Pacira BioSciences steady, with only small tweaks to assumptions around revenue growth, profit margins and future P/E that support this unchanged view. What's in the News Pacira BioSciences entered an agreement with LG Chem that gives LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.Pacira BioSciences: Mispriced On Generic Risks That Are Years Away
Feb 09PCRX: Asia Partnerships And Pipeline Progress Will Drive Future Upside Potential
Analysts have reiterated a US$38.00 price target for Pacira BioSciences, citing slightly updated assumptions for revenue growth, profit margin, and future P/E that collectively leave their overall valuation view unchanged. What's in the News Pacira entered an agreement with LG Chem, giving LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets, with Pacira receiving an upfront payment, transfer price, and tiered royalties while LG Chem handles regulatory filings in South Korea and Thailand within six months (Client Announcements).PCRX: Asia Partnership And Pipeline Advances Will Drive Future Upside Potential
Narrative Update Analysts have kept their price target for Pacira BioSciences broadly steady around $38.00, citing slightly higher modeled revenue growth, a modestly lower profit margin outlook, and a similar forward P/E assumption. What’s in the News Pacira entered an agreement with LG Chem, granting LG Chem exclusive rights to commercialize EXPAREL in select Asia Pacific markets.Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive
Jan 17
PCRX: Share Buybacks And Activist Pressure Will Support Future Upside Potential
Analysts have kept their fair value estimate for Pacira BioSciences steady at $38.00. The latest price target is grounded in updated assumptions for slightly different revenue growth, profit margin expectations, and a higher future P/E multiple.PCRX: Activist Pressure And Share Buybacks Will Unlock Future Upside Potential
Analysts have modestly raised their price target on Pacira BioSciences to $38.00 from $36.00, citing expectations for slightly stronger long term profitability despite a somewhat more conservative revenue growth outlook and valuation multiple. What's in the News Activist investor DOMA Perpetual Capital Management sent a letter to Pacira's board urging the company to hire bankers and pursue a full sale process, citing persistent underperformance and overspending (Key Developments).Pacira BioSciences' (NASDAQ:PCRX) Strong Earnings Are Of Good Quality
Nov 13
Policy Changes And Partnerships Will Expand Ambulatory Market Reach
The slight decrease in consensus revenue growth expectations and a lower future P/E multiple have led analysts to reduce their fair value estimate for Pacira BioSciences from $30.60 to $29.00. What's in the News Pacira completed a $50.04 million buyback, repurchasing 1,955,589 shares (4.23%) under its May 2025 authorization and previously completed a $25 million buyback (837,240 shares, 1.8%) under its May 2024 authorization.Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Quite Sensibly
Jun 11Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
Apr 09Pacira BioSciences, Inc. (NASDAQ:PCRX) Looks Inexpensive But Perhaps Not Attractive Enough
Apr 07Pacira BioSciences: Back On An Uptrend After Positive Developments
Mar 14Pacira BioSciences (NASDAQ:PCRX) Has A Rock Solid Balance Sheet
Jan 30Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 03Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Nov 25
EXPAREL's Calculated Expansion And Innovative R&D Bolster Market Dominance Amidst Challenges
Expanding EXPAREL utilization in outpatient settings and through GPO partnerships aims to enhance revenue by increasing market penetration and affordability.Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 06Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Jul 23These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely
Jun 07Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$7m |
| Sep 30 2025 | n/a | n/a | US$21m |
| Jun 30 2025 | n/a | n/a | -US$127m |
| Mar 31 2025 | n/a | n/a | -US$104m |
| Dec 31 2024 | US$16m | US$897k | -US$100m |
Compensation vs Market: Frank's total compensation ($USD15.94M) is above average for companies of similar size in the US market ($USD3.70M).
Compensation vs Earnings: Insufficient data to compare Frank's compensation with company performance.
CEO
Frank Lee (57 yo)
2.3yrs
Tenure
US$15,944,347
Compensation
Mr. Frank D. Lee served as an Independent Director at Bolt Biotherapeutics, Inc. since November 2021 until September 2024. He is Independent Director of Bausch Health Companies Inc. from May 14, 2024. He i...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$15.94m | 0.21% $ 2.2m | |
| Chief Financial Officer | 1.5yrs | US$3.16m | 0.26% $ 2.6m | |
| Principal Accounting Officer & Senior VP of Finance | 14.1yrs | US$2.56m | 0.017% $ 172.9k | |
| Chief Administrative Officer & Secretary | 11.5yrs | US$3.61m | 0% $ 0 | |
| Chief Medical Officer | 4.8yrs | US$2.88m | 0.13% $ 1.3m | |
| Head of Investor Relations | no data | no data | no data | |
| Chief Legal & Compliance Officer | 4.3yrs | US$2.05m | no data | |
| Chief Manufacturing Officer | 3yrs | no data | no data | |
| Chief Business Officer | 1.3yrs | no data | no data | |
| Chief Commercial Officer | 1.3yrs | no data | 0.022% $ 219.3k |
3.0yrs
Average Tenure
52yo
Average Age
Experienced Management: PCRX's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$15.94m | 0.21% $ 2.2m | |
| Independent Chair of the Board | 14.8yrs | US$389.01k | 0.043% $ 441.3k | |
| Independent Director | 12.8yrs | US$390.61k | 0.049% $ 494.5k | |
| Independent Director | 6.6yrs | US$350.01k | 0.013% $ 132.2k | |
| Independent Director | 2.5yrs | US$365.01k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$365.43k | 0.013% $ 131.5k | |
| Independent Director | 2.5yrs | US$362.01k | 0.0071% $ 72.3k | |
| Independent Director | 8.8yrs | US$374.01k | 0.035% $ 351.3k | |
| Independent Director | 2.5yrs | US$373.97k | 0.0049% $ 50.3k | |
| Independent Director | less than a year | no data | no data |
2.5yrs
Average Tenure
59.5yo
Average Age
Experienced Board: PCRX's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 12:51 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pacira BioSciences, Inc. is covered by 29 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jenna Davidner | Barclays |
| Anita Dushyanth | Berenberg |
| Gary Nachman | BMO Capital Markets Equity Research |